{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:34:55Z","timestamp":1752550495528,"version":"3.37.3"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10928-020-09671-7","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T06:02:42Z","timestamp":1579500162000},"page":"91-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Latent process model of the 6-minute walk test in Duchenne muscular dystrophy"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6084-7172","authenticated-orcid":false,"given":"Janelle L.","family":"Lennie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Mondick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc R.","family":"Gastonguay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"issue":"7","key":"9671_CR1","doi-asserted-by":"crossref","first-page":"e102737","DOI":"10.1371\/journal.pone.0102737","volume":"9","author":"P Sharma","year":"2014","unstructured":"Sharma P, Basu S, Mitchell RW, Stelmack GL, Anderson JE, Halayko AJ (2014) Role of dystrophin in airway smooth muscle phenotype, contraction and lung function. PLoS ONE 9(7):e102737","journal-title":"PLoS ONE"},{"issue":"1","key":"9671_CR2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, DMD Care Considerations Working Group (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9(1):77\u201393","journal-title":"Lancet Neurol"},{"issue":"6","key":"9671_CR3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/mus.21808","volume":"42","author":"CM MCDonald","year":"2010","unstructured":"MCDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Atkinson L, Elfring GL, Reha A, Miller LL (2010) The 6-minute walk test in Duchenne\/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 42(6):966\u2013974","journal-title":"Muscle Nerve"},{"issue":"8","key":"9671_CR4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.nmd.2013.05.006","volume":"23","author":"N Goemans","year":"2013","unstructured":"Goemans N, van den Hauwe M, Wilson R, van Impe A, Klingels K, Buyse G (2013) Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscul Disord 23(8):618\u2013623","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"9671_CR5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.0b013e318225ab2e","volume":"77","author":"E Mazzone","year":"2011","unstructured":"Mazzone E, Vasco G, Sormani MP, Torrente Y, Berardinelli A, Messina S, D\u2019Amico A, Doglio L, Politano L, Cavallaro F, Frosini S, Bello L, Bonfiglio S, Zucchini E, De Sanctis R, Scutifero M, Bianco F, Rossi F, Motta MC, Sacco A, Donati MA, Mongini T, Pini A, Battini R, Pegoraro E, Pane M, Gasperini S, Previtali S, Napolitano S, Martinelli D, Bruno C, Vita G, Comi G, Bertini E, Mercuri E (2011) Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 77(3):250\u2013256","journal-title":"Neurology"},{"issue":"10","key":"9671_CR6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","volume":"13","author":"T Voit","year":"2014","unstructured":"Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, De Kimpe SJ, Eagle M, Guglieri M, Hood S, Liefaard L, Lourbakos A, Morgan A, Nakielny J, Quarcoo N, Ricotti V, Rolfe K, Servais L, Wardell C, Wilson R, Wright P, Kraus JE (2014) Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 13(10):987\u2013996","journal-title":"Lancet Neurol"},{"issue":"5","key":"9671_CR7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Corridore M, Kean JR, Allen HD, Shilling C, Melia KR, Sazani P, Saoud JB, Kaye EM, Eteplirsen Study Group (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74(5):637\u2013647","journal-title":"Ann Neurol"},{"issue":"12","key":"9671_CR8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2(12):731\u2013740","journal-title":"Lancet Neurol"},{"issue":"3","key":"9671_CR9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","volume":"53","author":"A Aartsma-Rus","year":"2016","unstructured":"Aartsma-Rus A, Ginjaar IB, Bushby K (2016) The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet 53(3):145\u2013151","journal-title":"J Med Genet"},{"issue":"1","key":"9671_CR10","doi-asserted-by":"crossref","first-page":"e83400","DOI":"10.1371\/journal.pone.0083400","volume":"9","author":"M Pane","year":"2014","unstructured":"Pane M, Mazzone ES, Sormani MP, Messina S, Vita GL, Fanelli L, Berardinelli A, Torrente Y, D\u2019Amico A, Lanzillotta V, Viggiano E, D\u2019Ambrosio P, Cavallaro F, Frosini S, Bello L, Bonfiglio S, Scalise R, De Sanctis R, Rolle E, Bianco F, Van der Haawue M, Magri F, Palermo C, Rossi F, Donati MA, Alfonsi C, Sacchini M, Arnoldi MT, Baranello G, Mongini T, Pini A, Battini R, Pegoraro E, Previtali SC, Napolitano S, Bruno C, Politano L, Comi GP, Bertini E, Morandi L, Gualandi F, Ferlini A, Goemans N, Mercuri E (2014) 6 minute walk test in Duchenne MD patients with different mutations: 12 month changes. PLoS ONE 9(1):e83400","journal-title":"PLoS ONE"},{"issue":"9","key":"9671_CR11","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/humu.23561","volume":"39","author":"RT Wang","year":"2018","unstructured":"Wang RT, Barthelemy F, Martin AS, Douine ED, Eskin A, Lucas A, Lavigne J, Peay H, Khanlou N, Sweeney L, Cantor RM, Miceli MC, Nelson SF (2018) DMD genotype correlations from the Duchenne registry: endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype. Hum Mutat 39(9):1193\u20131202","journal-title":"Hum Mutat"},{"issue":"1","key":"9671_CR12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3233\/JND-140002","volume":"1","author":"JC van den Bergen","year":"2014","unstructured":"van den Bergen JC, Ginjaar HB, Niks EH, Aartsma-Rus A, Verschuuren JJGM (2014) Prolonged ambulation in Duchenne patients with a mutation amenable to exon 44 skipping. J Neuromuscul Dis 1(1):91\u201394","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"9671_CR13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JND-150100","volume":"2","author":"L Servais","year":"2015","unstructured":"Servais L, Montus M, Guiner CL, Ben Yaou R, Annoussamy M, Moraux A, Hogrel JY, Seferian AM, Zehrouni K, Le Moing AG, Gidaro T, Vanhulle C, Laugel V, Butoianu N, Cuisset JM, Sabouraud P, Cances C, Klein A, Leturcq F, Moullier P, Voit T (2015) Non-ambulant Duchenne patients theoretically treatable by exon 53 skipping have severe phenotype. J Neuromuscul Dis 2(3):269\u2013279","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"9671_CR14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","volume":"87","author":"L Bello","year":"2016","unstructured":"Bello L, Morgenroth LP, Gordish-Dressman H, Hoffman EP, McDonald CM, Cirak S, CINRG Investigators (2016) DMD genotypes and loss of ambulation in the CINRG Duchenne natural history study. Neurology 87(4):401\u2013409","journal-title":"Neurology"},{"issue":"4","key":"9671_CR15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mus.21544","volume":"41","author":"CM McDonald","year":"2010","unstructured":"McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, Atkinson L, Reha A, Hirawat S, Miller LL (2010) The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 41(4):500\u2013510","journal-title":"Muscle Nerve"},{"issue":"4","key":"9671_CR16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, Connolly AM, Day JW, Flanigan KM, Goemans N, Jones KJ, Mercuri E, Quinlivan R, Renfroe JB, Russman B, Ryan MM, Tulinius M, Voit T, Moore SA, Lee Sweeney H, Abresch RT, Coleman KL, Eagle M, Florence J, Gappmaier E, Glanzman AM, Henricson E, Barth J, Elfring GL, Reha A, Spiegel RJ, O\u2019donnell MW, Peltz SW, Mcdonald CM, PTC124-GD-007-DMD STUDY GROUP (2014) Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50(4):477\u2013487","journal-title":"Muscle Nerve"},{"issue":"12","key":"9671_CR17","doi-asserted-by":"crossref","first-page":"e115200","DOI":"10.1371\/journal.pone.0115200","volume":"9","author":"MA Brehm","year":"2014","unstructured":"Brehm MA, Kempen JCE, van der Kooi AJ, de Groot IJM, van den Bergen JC, Verschuuren JJGM, Niks EH, Harlaar J (2014) Age-related longitudinal changes in metabolic energy expenditure during walking in boys with Duchenne muscular dystrophy. PLoS ONE 9(12):e115200","journal-title":"PLoS ONE"},{"issue":"1","key":"9671_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.nmd.2012.10.019","volume":"23","author":"N Goemans","year":"2013","unstructured":"Goemans N, Klingels K, van den Hauwe M, Van Orshoven A, Vanpraet S, Feys H, Buyse G (2013) Test-retest reliability and developmental evolution of the 6-min walk test in caucasian boys aged 5\u201312 years. Neuromuscul Disord 23(1):19\u201324","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"9671_CR19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mus.23902","volume":"48","author":"CM Mcdonald","year":"2013","unstructured":"Mcdonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, Glanzman AM, Spiegel R, Barth J, Elfring G, Others (2013) The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48(3):343\u2013356","journal-title":"Muscle Nerve"},{"key":"9671_CR20","doi-asserted-by":"crossref","first-page":"e108205","DOI":"10.1371\/journal.pone.0108205","volume":"9","author":"M Pane","year":"2014","unstructured":"Pane M, Mazzone ES, Sivo S, Sormani MP, Messina S, Damico A, Carlesi A, Vita G, Fanelli L, Berardinelli A, Torrente Y, Lanzillotta V, Viggiano E, Dambrosio P, Cavallaro F, Frosini S, Barp A, Bonfiglio S, Scalise R, De Sanctis R, Rolle E, Graziano A, Magri F, Palermo C, Rossi F, Donati MA, Sacchini M, Arnoldi MT, Baranello G, Mongini T, Pini A, Battini R, Pegoraro E, Previtali S, Bruno C, Politano L, Comi GP, Bertini E, Mercuri E, (2014) Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS ONE 9:e108205","journal-title":"PLoS ONE"},{"key":"9671_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/currents.md.e1e8f2be7c949f9ffe81ec6fca1cce6a","author":"RT Wang","year":"2014","unstructured":"Wang RT, Silverstein\u00a0Fadlon CA, Ulm JW, Jankovic I, Eskin A, Lu A, Rangel\u00a0Miller V, Cantor RM, Li N, Elashoff R, Martin AS, Peay HL, Halnon N, Nelson SF (2014) Online self-report data for Duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits. PLoS Curr. https:\/\/doi.org\/10.1371\/currents.md.e1e8f2be7c949f9ffe81ec6fca1cce6a","journal-title":"PLoS Curr"},{"key":"9671_CR22","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3389\/fphar.2018.01402","volume":"9","author":"T Kameyama","year":"2018","unstructured":"Kameyama T, Ohuchi K, Funato M, Ando S, Inagaki S, Sato A, Seki J, Kawase C, Tsuruma K, Nishino I, Nakamura S, Shimazawa M, Saito T, Takeda S, Kaneko H, Hara H (2018) Efficacy of prednisolone in generated myotubes derived from fibroblasts of Duchenne muscular dystrophy patients. Front Pharmacol 9:1402","journal-title":"Front Pharmacol"},{"issue":"1","key":"9671_CR23","first-page":"9","volume":"31","author":"C Angelini","year":"2012","unstructured":"Angelini C, Peterle E (2012) Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol 31(1):9\u201315","journal-title":"Acta Myol"},{"key":"9671_CR24","unstructured":"Chmp E (2014) Translarna. Assessment report for initial marketing authorisation application.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/translarna-epar-public-assessment-report_en.pdf"},{"key":"9671_CR25","unstructured":"Food US, Administration D et al (2016) FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. FDA Med Bull. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm521263.htm"},{"issue":"9","key":"9671_CR26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/21678707.2017.1366310","volume":"5","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Sahenk Z, Rodino-Klapac LR (2017) Clinical trials of exon skipping in Duchenne muscular dystrophy. Expert Opin Orphan Drugs 5(9):683\u2013690","journal-title":"Expert Opin Orphan Drugs"},{"issue":"10101","key":"9671_CR27","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, Heydemann P, Kaminska A, Kirschner J, Muntoni F, Osorio AN, Schara U, Sejersen T, Shieh PB, Sweeney HL, Topaloglu H, Tulinius M, Vilchez JJ, Voit T, Wong B, Elfring G, Kroger H, Luo X, McIntosh J, Ong T, Riebling P, Souza M, Spiegel RJ, Peltz SW, Mercuri E, Clinical Evaluator Training Group, ACT DMD Study Group (2017) Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10101):1489\u20131498","journal-title":"Lancet"},{"issue":"4","key":"9671_CR28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/jpm8040041","volume":"8","author":"Y Echigoya","year":"2018","unstructured":"Echigoya Y, Lim KRQ, Nakamura A, Yokota T (2018) Multiple exon skipping in the Duchenne muscular dystrophy hot spots: prospects and challenges. J Pers Med 8(4):41","journal-title":"J Pers Med"},{"key":"9671_CR29","first-page":"001","volume":"Suppl 7","author":"KJ Brown","year":"2012","unstructured":"Brown KJ, Marathi R, Fiorillo AA, Ciccimaro EF, Sharma S, Rowlands DS, Rayavarapu S, Nagaraju K, Hoffman EP, Hathout Y (2012) Accurate quantitation of dystrophin protein in human skeletal muscle using mass spectrometry. J Bioanal Biomed Suppl 7:001","journal-title":"J Bioanal Biomed"},{"issue":"15","key":"9671_CR30","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1093\/hmg\/ddv154","volume":"24","author":"S Guiraud","year":"2015","unstructured":"Guiraud S, Squire SE, Edwards B, Chen H, Burns DT, Shah N, Babbs A, Davies SG, Wynne GM, Russell AJ, Elsey D, Wilson FX, Tinsley JM, Davies KE (2015) Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum Mol Genet 24(15):4212\u20134224","journal-title":"Hum Mol Genet"},{"key":"9671_CR31","unstructured":"Center for Drug Evaluation, Research (2019a) Rare diseases: natural history studies for drug development. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-natural-history-studies-drug-development. Accessed: 1 Aug 2019"},{"key":"9671_CR32","unstructured":"Center for Drug Evaluation, Research (2019b) Rare diseases: Common issues in drug development guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-common-issues-drug-development-guidance-industry. Accessed 1 Aug 2019"},{"key":"9671_CR33","unstructured":"Austin CP, Carrillo N, Charnas L, Chen KS, Darras BT, Eichler F, Escolar ML, Furlong P, Gallin JI, Groft SC, Gunay-Aygun M, Haslett P, Introne WJ, Kaufmann P, Kaye EM, Kishnani PS, Krischer JP, McDonald CM, McKew J, Moscicki RA, Pariser A, Paulsen JS, Pearce D, Rao GR, Shapiro EG, Stemhagen A, Summar ML, Tandon P, Walton MK (2012) Workshop summary. In Presented at the workshop on natural history studies of rare diseases: meeting the needs of drug development and research, Bethesda, MD"},{"key":"9671_CR34","unstructured":"Pariser A (2014) Rare disease and clinical trials. Presentation"},{"issue":"3\u20134","key":"9671_CR35","first-page":"121","volume":"3","author":"L Lapteva","year":"2018","unstructured":"Lapteva L, Vatsan R, Purohit-Sheth T (2018) Regenerative medicine therapies for rare diseases. Transl Sci Rare Dis 3(3\u20134):121\u2013132","journal-title":"Transl Sci Rare Dis"},{"issue":"4","key":"9671_CR36","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1198\/1085711032697","volume":"8","author":"M Davidian","year":"2003","unstructured":"Davidian M, Giltinan DM (2003) Nonlinear models for repeated measurement data: an overview and update. J Agric Biol Environ Stat 8(4):387","journal-title":"J Agric Biol Environ Stat"},{"key":"9671_CR37","doi-asserted-by":"crossref","DOI":"10.1201\/9780203745502","volume-title":"Nonlinear models for repeated measurement data","author":"M Davidian","year":"2017","unstructured":"Davidian M (2017) Nonlinear models for repeated measurement data. Routledge, Abingdon"},{"issue":"7","key":"9671_CR38","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100","journal-title":"PLoS Med"},{"key":"9671_CR39","unstructured":"Software A (2010) GraphClick\u2014graph and movie digitizer for mac OS X\u2014free download. http:\/\/www.arizona-software.ch\/graphclick\/. Accessed 27 Apr 2018"},{"key":"9671_CR40","volume-title":"Statistical rethinking: a Bayesian course with examples in R and Stan","author":"R McElreath","year":"2016","unstructured":"McElreath R (2016) Statistical rethinking: a Bayesian course with examples in R and Stan. CRC Press\/Taylor & Francis Group, Boca Raton"},{"key":"9671_CR41","doi-asserted-by":"crossref","DOI":"10.1201\/b16018","volume-title":"Bayesian data analysis","author":"A Gelman","year":"2013","unstructured":"Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB (2013) Bayesian data analysis, 3rd edn. CRC Press, Boca Raton","edition":"3"},{"key":"9671_CR42","unstructured":"R Core Team (2018) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/"},{"issue":"9","key":"9671_CR43","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ, DMD Italian Group, Trajectory Analysis Project (cTAP) (2016) Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. Neuromuscul Disord 26(9):576\u2013583","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"9671_CR44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/jnnp-2012-304230","volume":"84","author":"WC Liang","year":"2013","unstructured":"Liang WC, Nishino I (2013) Daily or alternative, that is the question: steroid therapy for Duchenne muscular dystrophy patients. J Neurol Neurosurg Psychiatry 84(6):591\u2013591","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"9671_CR45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","volume":"7","author":"A Gelman","year":"1992","unstructured":"Gelman A, Rubin DB (1992) Inference from iterative simulation using multiple sequences. Stat Sci 7(4):457\u2013472","journal-title":"Stat Sci"},{"issue":"4","key":"9671_CR46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"SP Brooks","year":"1998","unstructured":"Brooks SP, Gelman A (1998) General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7(4):434\u2013455. https:\/\/doi.org\/10.1080\/10618600.1998.10474787","journal-title":"J Comput Graph Stat"},{"issue":"1","key":"9671_CR47","first-page":"7","volume":"6","author":"M Plummer","year":"2006","unstructured":"Plummer M, Best N, Cowles K, Vines K (2006) CODA: convergence diagnosis and output analysis for MCMC. R News 6(1):7\u201311","journal-title":"R News"},{"key":"9671_CR48","unstructured":"Holford NH (2012) An introduction to visual predictive checks. http:\/\/holford.fmhs.auckland.ac.nz\/docs\/vpc-tutorial-and-datatop.pdf"},{"key":"9671_CR49","first-page":"S84","volume":"42","author":"KT Baron","year":"2015","unstructured":"Baron KT, Gastonguay MR (2015) Simulation from ODE-based population PK\/PD and systems pharmacology models in R with mrgsolve. J Pharmacokinet Pharmacodyn 42:S84\u2013S85","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"9671_CR50","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/psp4.12220","volume":"6","author":"L Hamuro","year":"2017","unstructured":"Hamuro L, Chan P, Tirucherai G, AbuTarif M (2017) Developing a natural history progression model for Duchenne muscular dystrophy using the six-minute walk test. CPT Pharmacomet Syst Pharmacol 6(9):596\u2013603","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"9671_CR51","unstructured":"Hajjar-Lennie JL, Fisher J, Gastonguay MR (2016) Modeling Duchenne muscular dystrophy disease progression as assessed by the 6-minute walk test. In: Presented at the annual meeting of the Population Approach Group in Europe"},{"issue":"25","key":"9671_CR52","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1002\/sim.5404","volume":"31","author":"JJ Lee","year":"2012","unstructured":"Lee JJ, Chu CT (2012) Bayesian clinical trials in action. Stat Med 31(25):2955\u20132972","journal-title":"Stat Med"},{"issue":"sup1","key":"9671_CR53","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/00031305.2019.1566091","volume":"73","author":"SJ Ruberg","year":"2019","unstructured":"Ruberg SJ, Harrell FE, Gamalo-Siebers M, LaVange L, Jack Lee J, Price K, Peck C (2019) Inference and decision making for 21st-century drug development and approval. Am Stat 73(sup1):319\u2013327","journal-title":"Am Stat"},{"issue":"24","key":"9671_CR54","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1002\/sim.6225","volume":"33","author":"LV Hampson","year":"2014","unstructured":"Hampson LV, Whitehead J, Eleftheriou D, Brogan P (2014) Bayesian methods for the design and interpretation of clinical trials in very rare diseases. Stat Med 33(24):4186\u20134201","journal-title":"Stat Med"},{"issue":"7748","key":"9671_CR55","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41586-019-00857-9","volume":"567","author":"V Amrhein","year":"2019","unstructured":"Amrhein V, Greenland S, McShane B (2019) Scientists rise up against statistical significance. Nature 567(7748):305\u2013307","journal-title":"Nature"},{"key":"9671_CR56","unstructured":"Thompson LA (n.d.) Bayesian methods for making inferences about rare diseases in pediatric populations. https:\/\/www.fda.gov\/media\/87358\/download"},{"key":"9671_CR57","unstructured":"Mutsvari T (n.d.) The value of Bayesian statistics for assessing comparability. In: Presented on behalf of European Federation of Statisticians in the Pharmaceutical Industry Working Group"},{"key":"9671_CR58","unstructured":"Chakravarty A (2018) Promoting the use of complex innovative designs in clinical trials. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/promoting-use-complex-innovative-designs-clinical-trials"},{"issue":"1","key":"9671_CR59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1214\/088342304000000044","volume":"19","author":"DA Berry","year":"2004","unstructured":"Berry DA (2004) Bayesian statistics and the efficiency and ethics of clinical trials. Stat Sci 19(1):175\u2013187","journal-title":"Stat Sci"},{"issue":"8","key":"9671_CR60","doi-asserted-by":"crossref","first-page":"e003563","DOI":"10.1161\/CIRCOUTCOMES.117.003563","volume":"10","author":"JA Bittl","year":"2017","unstructured":"Bittl JA, He Y (2017) Bayesian analysis: a practical approach to interpret clinical trials and create clinical practice guidelines. Circ Cardiovasc Qual Outcomes 10(8):e003563","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"9671_CR61","volume-title":"An overview of Bayesian adaptive clinical trial design","author":"RJ Lewis","year":"2012","unstructured":"Lewis RJ, Berry\u00a0Consultants LLC (2012) An overview of Bayesian adaptive clinical trial design. Berry Consultants, Austin"},{"issue":"3","key":"9671_CR62","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/biostatistics\/kxy009","volume":"20","author":"MA Psioda","year":"2019","unstructured":"Psioda MA, Ibrahim JG (2019) Bayesian clinical trial design using historical data that inform the treatment effect. Biostatistics 20(3):400\u2013415","journal-title":"Biostatistics"},{"key":"9671_CR63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1146\/annurev.pharmtox.40.1.209","volume":"40","author":"NH Holford","year":"2000","unstructured":"Holford NH, Kimko HC, Monteleone JP, Peck CC (2000) Simulation of clinical trials. Annu Rev Pharmacol Toxicol 40:209\u2013234","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"Suppl 4","key":"9671_CR64","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.21037\/tcr.2019.05.17","volume":"8","author":"DT Chen","year":"2019","unstructured":"Chen DT, Schell MJ, Fulp WJ, Pettersson F, Kim S, Gray JE, Haura EB (2019) Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial. Transl Cancer Res 8(Suppl 4):S404\u2013S420","journal-title":"Transl Cancer Res"},{"issue":"8","key":"9671_CR65","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/sim.8050","volume":"38","author":"M Quintana","year":"2019","unstructured":"Quintana M, Shrader J, Slota C, Joe G, McKew JC, Fitzgerald M, Gahl WA, Berry S, Carrillo N (2019) Bayesian model of disease progression in GNE myopathy. Stat Med 38(8):1459\u20131474","journal-title":"Stat Med"},{"issue":"1","key":"9671_CR66","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12874-019-0714-z","volume":"19","author":"C Brard","year":"2019","unstructured":"Brard C, Hampson LV, Gaspar N, Le Deley MC, Le Teuff G (2019) Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study. BMC Med Res Methodol 19(1):85","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"9671_CR67","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/2168479018778282","volume":"52","author":"J Lim","year":"2018","unstructured":"Lim J, Walley R, Yuan J, Liu J, Dabral A, Best N, Grieve A, Hampson L, Wolfram J, Woodward P, Yong F, Zhang X, Bowen E (2018) Minimizing patient burden through the use of historical subject-level data in innovative confirmatory clinical trials: review of methods and opportunities. Ther Innov Regul Sci 52(5):546\u2013559","journal-title":"Ther Innov Regul Sci"},{"key":"9671_CR68","unstructured":"Center for Devices, Radiological Health (2019) Guidance for the use of Bayesian statistics in medical device clinical. http:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-use-bayesian-statistics-medical-device-clinical-trials. Accessed 26 Nov 2019"},{"key":"9671_CR69","unstructured":"Sarepta\u00a0Therapeutics I (2016) Eteplirsen briefing document NDA 206488. Tech. rep., Sarepta Therapeutics, Inc., Cambridge"},{"key":"9671_CR70","unstructured":"FDA (2018) Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment guidance for industry. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)"},{"issue":"11","key":"9671_CR71","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/dmcn.12213","volume":"55","author":"A Mayhew","year":"2013","unstructured":"Mayhew A, Mazzone ES, Eagle M, Duong T, Ash M, Decostre V, Vandenhauwe M, Klingels K, Florence J, Main M, Bianco F, Henrikson E, Servais L, Campion G, Vroom E, Ricotti V, Goemans N, McDonald C, Mercuri E, Performance of the Upper Limb Working Group (2013) Development of the performance of the upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 55(11):1038\u20131045","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"9671_CR72","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/dmcn.13277","volume":"59","author":"K Klingels","year":"2017","unstructured":"Klingels K, Mayhew AG, Mazzone ES, Duong T, Decostre V, Werlauff U, Vroom E, Mercuri E, Goemans NM, Upper Limb Clinical Outcome Group (2017) Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD upper limb PROM. Dev Med Child Neurol 59(2):224\u2013231","journal-title":"Dev Med Child Neurol"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-020-09671-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-020-09671-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-020-09671-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:45:33Z","timestamp":1611017133000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-020-09671-7"}},"subtitle":["A Bayesian approach to quantifying rare disease progression"],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["9671"],"URL":"https:\/\/doi.org\/10.1007\/s10928-020-09671-7","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"type":"print","value":"1567-567X"},{"type":"electronic","value":"1573-8744"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"17 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}